Praxis precision medicines, inc. announces inducement grants under nasdaq listing rule 5635(c)(4)

Boston, june 04, 2025 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on june 2, 2025, the compensation committee of praxis' board of directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the praxis precision medicines, inc. 2024 inducement plan (the 2024 inducement plan). the restricted stock unit award was granted as inducement material to the employee's entering into employment with praxis in accordance with nasdaq listing rule 5635(c)(4).
PRAX Ratings Summary
PRAX Quant Ranking